TY - JOUR
T1 - Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors
AU - Sharma, Nancy
AU - Naraev, Boris G.
AU - Engelman, Eric G.
AU - Zimmerman, M. Bridget
AU - Bushnell, David L.
AU - O'Dorisio, Thomas M.
AU - O'Dorisio, M. Sue
AU - Menda, Yusuf
AU - Müller-Brand, Jan
AU - Howe, James R.
AU - Halfdanarson, Thorvardur R.
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Objectives: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). Methods: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. Results: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and themedian time to progressionwas 23.9months.Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. Conclusions: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.
AB - Objectives: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). Methods: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. Results: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and themedian time to progressionwas 23.9months.Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. Conclusions: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.
KW - Chromogranin A
KW - Neuroendocrine tumors
KW - PRRT
KW - Pancreastatin
KW - Peptide receptor radionuclide therapy
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84992128564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992128564&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000734
DO - 10.1097/MPA.0000000000000734
M3 - Article
C2 - 27759712
AN - SCOPUS:84992128564
SN - 0885-3177
VL - 46
SP - 151
EP - 156
JO - Pancreas
JF - Pancreas
IS - 2
ER -